Samuels, Saul S.
April 1957
Angiology;Apr1957, Vol. 8 Issue 2, p201
Academic Journal
A preliminary report is offered relative to the beneficial effect of a tranquilizing drug, phenoglycodol, in the relief of the disabling symptom of intermittent claudication.


Related Articles

  • DISCUSSION. Andreozzi, G. M. // Angiology;Nov1998, Vol. 49 Issue 11, p895 

    Discusses the background in treating severe claudication with prostanoids. Pathophysiology of severe claudication; Capacity of prostanoids to restore the microcirculatory autoregulation; Opening of the possibility of increasing the availability of endovascular procedures.

  • Treatment of intermittent claudication. Karthikeyan, G.; Eikelboom, John W. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/21/2009, p671 

    The authors reflect on methods which are used to treat intermittent claudication. They suggest that any methods that are used should improve the patient's symptoms and decrease the risk of cardiovascular problems. They argue that the most important goal of medical treatment in patients with...

  • Efficacy of Cilostazol for Intermittent Claudication. Apgar, Barbara // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1124 

    Discusses the study `A New Pharmacological Treatment for Intermittent Claudication: Results of a Randomized, Multicenter Trial,' by H.G. Beebe and colleagues published in the September 27, 1999 issue of the `Archives of Internal Medicine.'

  • Effects of Pentoxifylline on Severe Intermittent Claudication. Reich, Theobald; Gilings, Dennis // Angiology;Sep1987, Vol. 38 Issue 9, p651 

    Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication (< 70 m...

  • Comparison of Safety and Efficacy of Buflomedil and Naftidrofuryl in the Treatment of Intermittent Claudication. Rosas, Guillermo; Cerdeyra, Cristina; Lucas, Miguel A.; Parano, Jorge R.; Villa, Juan J. // Angiology;May1981, Vol. 32 Issue 5, p291 

    In a group of 58 patients with peripheral arteriopathies, we have studied efficacy and safety of buflomedil hydrochloride and naftidrofuryl. Both drugs have been shown to have vasoactive properties evaluated through walking capacity and time of hyperemia. According to our results, buflomedil is...

  • A focus on risk factor management. Belch, Jill J. F.; Creager, Mark A. // Vascular Medicine;2004, Vol. 9 Issue 3, p169 

    This article reports that peripheral arterial disease (PAD) and its most common manifestation, intermittent claudication (IC), are associated with considerable morbidity and mortality. The patient with PAD has well-documented risk factors for atherosclerosis. Because of these, combined with the...

  • INTERMITTENT CLAUDICATION. Bennett-Jones, N.; Murphy, A. Furber // Angiology;Jun1957, Vol. 8 Issue 3, p291 

    This is a survey of 200 consecutive male patients attending a clinic suffering from intermittent claudication. The following points are discussed: 1. Etiology, especially in relation to type of work and tobacco and alcohol consumption. 2. Methods of investigation. 3. Technique and equipment...

  • Comparative Evaluation of Pentoxifylline, Buflomedil, and Nifedipine in the Treatment of Intermittent Claudication of the Lower Limbs. Chacón-Quevedo, A.; Eguaras, M. G.; Calleja, F.; Garcia, M. A.; Roman, M.; Casares, J.; Muñoz, I.; Concha, M. // Angiology;Jul1994, Vol. 45 Issue 7, p647 

    In the light of the current controversy surrounding the use of hemorheologic and vasodilator drugs in the treatment of peripheral arteriosclerosis, a comparative study was designed in order to evaluate the efficacy of pentoxifylline, buflomedil, and nifedipine in 45 patients with peripheral...

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics